According to the Zhitong Finance APP, Asia Pharmaceutical-B (06855) rose more than 7%, as of the time of writing, up 7.16%, at HK$35.9, with a turnover of HK$50.4882 million.

On the news front, Asia Pharmaceutical recently announced the clinical research results of its innovative Class 1 new drug Orelabatinib (trade name: Nalitinib; development code: HQP1351) for the treatment of succinate dehydrogenase (SDH)-deficient gastro-intestinal stromal tumors (GIST) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting in Europe. Orelabatinib has shown sustained clinical efficacy in SDH-deficient GIST and provided a benchmark for future research on this rare disease. MOA studies have shown that Orelabatinib exerts anti-tumor activity by modulating multiple signaling pathways involved in angiogenesis, apoptosis, proliferation, and survival.

In the first half of this year, Asia Pharmaceutical achieved a revenue of RMB 824 million, a YoY increase of 477%; it achieved its first profit in the period with a net income of RMB 163 million. During the period, the commercialization of Nalitinib progressed rapidly, with sales revenue of RMB 113 million, a 120% increase compared to the second half of last year, and a 5% increase compared to the first half of last year on a YoY basis. CICC pointed out that Nalitinib has been successfully launched in the domestic market. Nalitinib's new indication for TKI resistance/intolerance in CML-CP is expected to be included in the medical insurance coverage in 2025, further benefiting more patients.